You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
海思科(002653.SZ):與Aquestive合作在中國開發和商業化ALS藥物

格隆匯3月3日丨海思科(002653.SZ)公佈,公司與美國Aquestive Therapeutics, Inc.(簡稱“Aquestive”)簽署了治療肌萎縮側索硬化症(“ALS”,俗稱“漸凍症”)的利魯唑口腔膜EXSERVAN(簡稱“EXSERVAN”)的《License, Developmentand Supply Agreement》。海思科將負責EXSERVAN在中國的註冊和商業化活動。Aquestive將作為該產品的獨家制造商和供應商。

交易條款總價值包括首付款和監管里程碑付款總計數百萬美金,以及一定金額的銷售分成。公司與Aquestive此次合作在中國開發和商業化這種差異化ALS藥物,有助於擴大公司的CNS產品組合,併為ALS患者提供改良的利魯唑製劑。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account